Evidence map›Paper›PMID 2327474›Full record

ArticleThe American journal of pathology1990

Sequential events in the pathogenesis of streptococcal cell wall-induced arthritis and their modulation by bis(5-amidino-2-benzimidazolyl)methane (BABIM).

J D Geratz, R R Tidwell, J H Schwab, S K Anderle, K B Pryzwansky

Abstract read
In one paragraph

Article in The American journal of pathology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs.Antimicrobial agents and chemotherapy · 1998
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J D GeratzDepartment of Pathology, University of North Carolina, Chapel Hill 27599.
R R Tidwell
J H Schwab
S K Anderle
K B Pryzwansky
University of North Carolina at Chapel Hill · US

Funding

SUPPRESSION OF EROSIVE ARTHRITIS BY PROTEASE INHIBITORSR01AR039460 · NIAMS · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI GERATZ, JOACHIM D · 1988 to 1992
–
NIAMS NIH HHS AR-39460
6 · The paper itself

Abstract

This report builds on the authors' earlier discovery of bis(5-amidino-2-benzimidazolyl)methane (BABIM) as a strong suppressive agent for streptococcal cell wall fragment-induced arthritis in the Lewis rat. As a synthetic inhibitor of trypsinlike proteases, BABIM opens up a new route to the control of inflammatory joint disease. To gain a deeper insight into the function of the compound, the authors have now studied its influence on the sequential development of the joint changes and the associated lesions in spleen and liver. Bis(5-amidino-2-benzimidazolyl)methane is shown to block acute synovitis, to retard and reduce granuloma formation in spleen and liver, to decrease neutrophilic leukocytosis, and to diminish hemopoietic hyperplasia in the bone, and thus also to mitigate the distinctive osteoclastic and chondroclastic events. The compound does not interfere with the splenic immune response, the temporary rise in hepatocytic mitotic activity, or the organ deposition of streptococcal cell walls.

Indexed as

AnimalsArthritisBenzimidazolesCell WallLeukocyte CountLiverPeptidoglycanPolysaccharides, BacterialProtease InhibitorsRatsRats, Inbred LewSpleenStreptococcusSynovial MembraneTime FactorsBenzimidazolesbis(5-amidino-2-benzimidazolyl)methanePeptidoglycanPolysaccharides, BacterialProtease Inhibitors

Identifiers

PMID2327474
PMCPMC1877637
OpenAlexW253236530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.